Napredna pretraga

Pregled bibliografske jedinice broj: 180846

Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.


Čulić, Srđana; Čulić, Vida; Armanda, V.; Kuljiš, Dubravka; Pešutić-Pisac, Valdi; Janković, Stipan
Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl. // Pediatric hematology and oncology, 20 (2003), 4; 339-344 (recenziran, članak, stručni)


Naslov
Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.

Autori
Čulić, Srđana ; Čulić, Vida ; Armanda, V. ; Kuljiš, Dubravka ; Pešutić-Pisac, Valdi ; Janković, Stipan

Izvornik
Pediatric hematology and oncology (0888-0018) 20 (2003), 4; 339-344

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni

Ključne riječi
Anti-CD20 antybody; non-Hodgkin lymphoma

Sažetak
Intravenous therapy with the anti-CD20 antibody Rituximab has been recently approved for the treatment of CD20 positive non-Hodgkin's lymphoma (NHL) in adults but not in children. The authors present the benefits of its application for mediastinal NHL CD 20+ with a local extension into the lung of a 10-year-old-girl. Receiving the chemotherapy according to study NHL-BFM-95 for high-risk lymphoma the girl did not reach complete remission. Before the last chemotherapy block was started, a computed tomography scan of the thorax showed residue in the right lung. Twenty-five days after the last chemotherapy she received Rituximab at a dose of 375 mg/m(2) by intravenous infusion once a week for a total of four doses without the adverse reactions. Complete remission was achieved. The patient was high risk with lung involvement of lymphoma suggesting a pure prognosis. The results suggest that Rituximab may improve the outcome in high-risk patients and appeared to be safe and effective in children also.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Projekt / tema
0141009
0216011

Ustanove
KBC Split,
Medicinski fakultet, Split

Citiraj ovu publikaciju

Čulić, Srđana; Čulić, Vida; Armanda, V.; Kuljiš, Dubravka; Pešutić-Pisac, Valdi; Janković, Stipan
Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl. // Pediatric hematology and oncology, 20 (2003), 4; 339-344 (recenziran, članak, stručni)
Čulić, S., Čulić, V., Armanda, V., Kuljiš, D., Pešutić-Pisac, V. & Janković, S. (2003) Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.. Pediatric hematology and oncology, 20 (4), 339-344.
@article{article, year = {2003}, pages = {339-344}, keywords = {anti-CD20 antybody, non-Hodgkin lymphoma}, journal = {Pediatric hematology and oncology}, volume = {20}, number = {4}, issn = {0888-0018}, title = {Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.}, keyword = {anti-CD20 antybody, non-Hodgkin lymphoma} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE